温胆汤联合氨磺必利治疗难治性精神分裂症的对照研究

Control study on refractory schizophrenia treated with wendantang and amisulpride

目的观察温胆汤联合氨磺必利治疗难治性精神分裂症的疗效和安全性。方法将72例难治性精神分裂症患者随机分为研究组和对照组,研究组口服温胆汤联合氨磺必利治疗,对照组单独口服氨磺必利治疗,观察12周。于治疗前、治疗后4、8、12周末观察阳性与阴性症状量表(PANSS)评分,观察两组治疗后临床疗效及不良反应情况。结果研究组治疗后有效率为72. 73%,对照组为51. 61%,两组比较差异有统计学意义(P <0. 05)。两组患者治疗12周后PANSS评分与本组治疗前比较均有降低,差异具有统计学意义(P <0. 01);两组患者治疗后各时间段评分比较,差异无统计学意义(P> 0. 05)。研究组锥外系反应震颤、静坐不能的发生率明显低于对照组(P <0. 05)。结论温胆汤联合氨磺必利治疗难治性精神分裂症疗效好,安全性高,是治疗难治性精神分裂症的一个新途径、新方法。

Objective To observe the therapeutic effects and safety on refractory schizophrenia treated with wendantang and amisulpride.Methods A total of72patients of refractory schizophrenia were randomized into a trial group and a control group.In the trial group,the combined medication of wendantang and amisulpride was used for oral administration.In the control group,only amisulpride was used for oral administration.The observation duration was12weeks.Separately,before treatment,in4,8and12weeks after treatment,PANSS scores of the positive and negative symptoms,the clinical effects after treatment and the adverse reactions were observed in the two groups.Results The effective rate was72.73%in the trial group and was51.61%in the control group after treatment,indicating the significant differences(P<0.05).In12weeks of treatment,PANSS scores were all reduced as compared within the group,indicating the significant differences(P<0.01).The scores were not different significantly at each time point after treatment between the two groups(P>0.05).In the trial group,the incidences of extrapyramidal reactive tremor and akathisia were lower remarkably than the control group(P<0.05).Conclusion The combined medication of wendantang and amisulpride is good in the therapeutic effects and high in safety for refractory schizophrenia.This therapeutic method is a new approach to the treatment of refractory schizophrenia.